Therefore, it is posited that BPC-157 may exhibit pro-angiogenic action by potentially promoting the expression and internalization of VEGFR2 and potentially activating the VEGFR2-Akt-eNOS signaling pathway
Researchers employ BPC-157 in defined in-vitro environments to study concentration-response relationships, pathway activation profiles, and interaction networks at the cellular and molecular level, strictly within laboratory assay designs and without any in-vivo context
Results from Radiesse injections for volumetric changes are visible right away, but the final result takes months to develop
its the potential for 1+1=3
An interesting point would be the use of the same dose range in BPC 157 studies [111]
But the most important answer is regulatory and medical: injectable GHK-Cu is not FDA-approved, and this article should not be used as self-injection instruction